MARKET

CDXS

CDXS

Codexis Inc
NASDAQ
3.700
+0.050
+1.37%
After Hours: 3.670 -0.03 -0.81% 16:04 07/26 EDT
OPEN
3.730
PREV CLOSE
3.650
HIGH
3.755
LOW
3.620
VOLUME
462.30K
TURNOVER
0
52 WEEK HIGH
4.910
52 WEEK LOW
1.450
MARKET CAP
261.06M
P/E (TTM)
-3.9312
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CDXS last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at CDXS last week (0708-0712)?
Weekly Report · 07/15 09:17
Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?
Codexis, Inc. (NASDAQ:CDXS) has US$28.1m of debt on its balance sheet. The company has a negative free cash flow of US$54m over the last 12 months. Codexis has a large amount of debt, but also has a healthy balance sheet of cash and short-term assets. Debt is an important factor in assessing how risky a company is. We've identified 3 warning signs with Codexis.
Simply Wall St · 07/12 11:25
Weekly Report: what happened at CDXS last week (0701-0705)?
Weekly Report · 07/08 09:18
Craig-Hallum Remains a Buy on Codexis (CDXS)
TipRanks · 07/02 13:16
Codexis to sell Pompe, Fabry assets to Crosswalk Therapeutics
Healthcare Codexis to sell Pompe, Fabry assets to Crosswalk Therapeutics in April 2023. Codexis said it has finalized a sales agreement with Crosswalk for its gene therapy programs for Fabry and Pompe disease. Crosswalk is led by former members of Takeda's rare disease unit.
Seeking Alpha · 07/01 21:28
Codexis Enters Asset Purchase Agreement With Crosswalk Therapeutics
Dow Jones · 07/01 20:55
Codexis Finalizes Purchase Agreement With Crosswalk Therapeutics For Gene Therapy Assets; Codexis Is Eligible To Receive Future Development And Commercial Milestone Payments In Addition To A Low-To-Mid Single-Digit Percentage Net Sales-Based Royalty
Codexis has entered into an asset purchase agreement with Crosswalk Therapeutics for the company's investigational Fabry and Pompe disease compounds. Codexis is eligible to receive future development and commercial milestone payments and a royalty on sales of the compounds. The company is a leading enzyme engineering company.
Benzinga · 07/01 20:11
More
About CDXS
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Webull offers Codexis Inc stock information, including NASDAQ: CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.